AAV-TH-DIO-hM3D(Gq)-EGFP-WPREs

What is AAV-TH-DIO-hM3D(Gq)-EGFP-WPREs?

A Cre-dependent adeno-associated virus that drives excitatory chemogenetic control of catecholaminergic neurons. It expresses the hM3D(Gq) DREADD under the TH promoter, with an EGFP reporter for expression verification. The receptor is membrane-targeted and activated only in Cre-expressing cells.

Research Background

This vector enables chemogenetic control of neuronal signaling and excitability through an engineered, ligand-gated receptor. Chemogenetic tools like hM3D(Gq) are well suited to experiments that call for sustained, minutes-to-hours modulation—situations where the fast, tightly timed control of optogenetics is not required.

Mechanism and Expected Readouts

Once expressed, hM3D(Gq) provides ligand-dependent control over downstream Gq signaling and cellular excitability. When designing experiments, consider your choice of ligand and dose, the onset and washout kinetics of the response, and the possibility of off-target effects at higher concentrations.

Expression Design and Interpretation

Promoter — TH: Enriches expression in catecholaminergic neurons, including dopaminergic and noradrenergic populations.

Expression control — Cre-dependent (DIO/FLEX): The transgene is inverted and activates only in cells that also express Cre recombinase; all other transduced cells stay silent.

Reporter/tag — EGFP: Green fluorescent protein (Ex ~488 nm / Em ~507 nm) for confirming expression, mapping morphology, and validating targeting.

Subcellular localization — Plasma membrane: The receptor is membrane-anchored; confirm surface expression by imaging.

Primary payload — hM3D(Gq): An excitatory, Cre-dependent chemogenetic receptor that supports ligand-driven modulation on a minutes-to-hours timescale. Where subcellular targeting elements are present, they can shape localization and should be verified by imaging in your own preparation.

Common Research Applications

This vector is used to drive sustained activation of defined cell populations, to study behavior over longer timescales (minutes to hours), and to dissect neuromodulatory pathways through receptor-specific signaling.

Experimental Considerations

Include vehicle controls and dose-response designs wherever possible, and build enough time into behavioral schedules to accommodate ligand onset and washout. Validate expression and function in a subset of animals or cultures before scaling up.

Controls and Validation

Recommended validation includes confirming the expression pattern and level, verifying functional activity with an assay matched to the payload (imaging, electrophysiology, pharmacology, or behavior), and running appropriate negative controls.

• Sales Terms and Conditions (PDF)
• SDS (PDF)

At present, the main purification approaches for rAAV include:

• Ultracentrifugation density-gradient methods, using cesium chloride (CsCl) or iodixanol as the gradient medium;
• Chemical reagent precipitation/extraction methods, mainly using PEG, ammonium sulfate, chloroform, etc.;
• Chromatographic purification methods, primarily based on affinity and ion-exchange principles.

Depending on customers’ different application needs, we can integrate multiple methods to produce high-titer, high-purity, high-quality rAAV viral products.

To choose a serotype, start with your target tissue and delivery route, then pick a capsid with a proven track record in that setting and benchmark 1–3 alternatives. For liver-directed systemic expression, AAV8 is a common first choice; for broad systemic delivery and strong cardiac performance, AAV9 is often preferred. For local CNS injections, AAV2 (or AAV1/2 for improved spread) is a reliable starting point, while rAAV2-retro is ideal when you need retrograde labeling from projection targets. For mouse brain-wide delivery by IV, AAV-PHP.eB is frequently used, and AAV-PHP.S is often selected for PNS/DRG-enriched programs. For muscle, AAV1, AAV6 (and AAV6 variants) or MyoAAV 2A are common starting points; for airway/lung, AAV5 or AAV6 are typical benchmarks. For ocular work, route matters: AAV-7m8 is often chosen for intravitreal retinal delivery, while AAV2/AAV5/Anc80L65 are common comparators depending on the target layer. If you’re unsure or working in a new model, include a broad performer like AAV-DJ and/or a small screening panel (e.g., PAN/BI30/SCH9) to quickly identify the best capsid in your exact system.

Can’t find the AAV you need—or require a custom design and packaging service? We offer end-to-end support for diverse research and therapeutic needs, including vector design and cloning, AAV packaging services (serotype/capsid selection and production), QC & characterization (project-appropriate testing and documentation), and library preparation for pooled or library-style workflows (project dependent). Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.